Brain Health & TB006

TB006 Brings Multifaceted Hope for Dementia and Beyond

TB006 is an investigational medicine offering a potentially anti-inflammatory approach to treating Alzheimer's disease (AD) and a wide range of dementias. This investigational drug targets Galectin-3 (Gal3), a protein with dual roles in the progression of these diseases:

1. Formation of harmful brain aggregates: Gal3 contributes to forming toxic oligomers and plaques, disrupting communication between neurons and leading to cognitive decline.

2. Regulation of inflammation: Gal3 over activation triggers excessive microglial activity and chronic neuroinflammation, further damaging neurons.

By selectively blocking Gal3, TB006 potentially disrupts both of these pathways. It potentially prevents harmful brain aggregates while reducing neuroinflammation, potentially reversing some damage and restoring cognitive function. Early clinical trials show promising results for treating various dementias, including:

• Vascular dementia

• Frontotemporal dementia

• Lewy body dementia

• Dementia with mixed pathology

Beyond these specific types, TB006's unique mechanism of action suggests its potential to benefit individuals with other dementias as well. This opens up exciting possibilities for the future of dementia treatment.

TB006 offers hope for millions of individuals and their families. It represents a potentially significant breakthrough in the fight against dementia, paving the way for a brighter future and improved quality of life for those affected by this debilitating condition.

What is the Expanded Access Program (EAP)?

Expanded access, also known as compassionate use, is a program that allows patients with severe or life-threatening illnesses to receive investigational medications outside of clinical trials. It provides access to these medications, which have not yet been approved by the FDA, when there are no other approved treatment options available. Patients eligible for this program may have already tried and failed approved medications, or they may be unable to take currently available medications due to side effects or contraindications. Additionally, expanded access programs cater to situations where no clinical trials are available or the patient does not meet the eligibility criteria for such trials. By granting access to investigational medications, these programs offer a compassionate approach to provide potential benefits to patients who have exhausted all other alternatives for their conditions.